PPIDT00408
Drug Information
| Name | Tislelizumab |
|---|---|
| Sequence | QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIYADGSTNYNPSLKSRVTISKDTSKNQVSLKLSSVTAADTAVYYCARAYGNYWYIDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPPVAGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVVHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK |
| DrugBank_ID | DB14922 |
| Type | biotech |
| Indication | Tislelizumab is indicated as monotherapy for the treatment of unresectable,[L49349, L50341] locally advanced,[L49349] or metastatic esophageal squamous cell carcinoma [L49349, L50341] in adults after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor, such as platinum-based chemotherapy.[L49349, L50341] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution, concentrate | Intravenous |
10 mg/ml
|
| Injection, solution, concentrate | Intravenous |
10 mg/1mL
|
| Injection, solution, concentrate | Intravenous |
100 mg
|